Fred launches third-party apps market for pharmacies
Australian pharmacy IT options supplier Fred IT Group has launched an internet market of third-party functions for pharmacies.
Known as Fred Market, the web-based hub has options which were authorised and examined to be used with Fred’s software program, together with apps and integrations for robots, eCommerce, enterprise intelligence, medical providers, drug data and drugs administration, loyalty and cost.
Third-party options come from Fred’s trusted vendor companions, specifically BD, Dataology, GuildLink, LifeSmart, MIMs, Modeus, Storbie, StrongRoom, Tyro, and Willach Pharmacy Options.
{The marketplace} will proceed to deliver on new software program companions and authorised functions because it expands.
College of South Australia researchers develop fibre sensors to remotely monitor sufferers
Scientists from the College of South Australia have developed tiny optical fibre sensors to remotely monitor the positions of sufferers coping with painful strain sores in their beds.
“Every year, hundreds of older Australians in hospitals and nursing properties expertise strain accidents, or ulcers, which take a very long time to heal and will be deadly. On the very least, these accidents may cause extreme ache, disrupt sleep, have an effect on their temper, in addition to their rehabilitation, mobility and high quality of life,” mentioned Dr Stephen Warren-Smith, the lead researcher behind the brand new expertise.
The fibre sensors are connected to the higher floor of a mattress to watch motion and report coronary heart and respiratory charges.
By selecting up their respiration, the unobtrusive sensors can detect when a affected person turns over, leaves a mattress, or stays immobile. Nurses will be prompted if a affected person has not moved for hours so they may regulate their place.
Present strategies to watch sufferers coping with strain sores use weight-based sensors, which can’t predict when a affected person leaves the mattress till their toes contact the ground. Digicam-based applied sciences are additionally getting used, though privateness is a serious concern.
EpiAxis Therapeutics, Peptilogics accomplice for AI drug discovery
Australian drug developer EpiAxis Therapeutics and Peptilogics, a US-based biotechnology firm, will harness AI in drug discovery to inhibit epigenetic oncology targets.
Their challenge will make use of Peptilogics’ AI platform Nautilus, along with EpiAxis’s experience in epigenetics, to advance drug discovery for cancers that escape present therapies via epigenetic change, together with metastatic breast most cancers.
“We’ll concentrate on lead optimisation utilizing Peptilogics’ Nautilus platform, which mixes proprietary deep generative fashions, predictive fashions, and biophysical simulation to design multiparameter-optimised peptides with [the] potential to handle traditionally difficult and novel drug targets,” mentioned Peptilogics CTO Nicholas Nystrom.
This partnership follows EpiAxis’s just lately concluded medical trial which for the primary time has used an epigenetic inhibitor alongside chemotherapy to deal with metastatic most cancers.
